GlassScriptPhysician profile
Benjamin F Walton
NPI 1427280007
$4,870.12
in general payments reported to CMS, 2019-2025
20 companies · $889 in 2025
The $889 reported for 2025 was more than what 77% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $278 · 2021: $1,247 · 2022: $767 · 2023: $752 · 2024: $579 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,164 · Education: $56.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,163.96 |
| Education | $56.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $1,135.94 | 2019-2025 | |
| Medtronic, INC. | $830.19 | 2021-2025 | Propel, Nuvent, Pteye Parathyroid Detection System |
| Optinose US, INC. | $519.49 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $457.54 | 2020-2025 | Dupixent |
| Acclarent, INC | $332.36 | 2019-2022 | |
| Genzyme Corporation | $299.58 | 2021-2025 | |
| Neurent Medical Limited | $252.99 | 2023-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
| Stryker Corporation | $183.77 | 2023-2025 | Scopis Ent, Xpress Loprofile, Clarifix Cryotherapy Device |
| Inspire Medical Systems, INC. | $149.46 | 2025 | Inspire |
| Alk-Abello, INC | $147.67 | 2019-2022 | |
| Abbvie INC. | $119.93 | 2021-2024 | Ubrelvy |
| Spirair, INC. | $114.20 | 2024-2025 | Septalign |
| Integra Lifesciences Corporation | $82.99 | 2024 | Trudi Probe, Inspira Air, Acclarent Aera |
| Kaleo, INC. | $64.54 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $57.59 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $34.59 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $33.03 | 2019-2021 | |
| Glaxosmithkline, LLC. | $21.60 | 2025 | Nucala |
| Hikma Pharmaceuticals USA | $16.38 | 2023 | Ryaltris |
| Intersect Ent, INC. | $16.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Walton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.